Aligos Therapeutics, Inc. Operating Lease, Liability, Current
Aligos Therapeutics, Inc. (ALGS) had Operating Lease, Liability, Current of $3.15 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Leases › Assets and Liabilities, Lessee
us-gaap:OperatingLeaseLiabilityCurrent · last filed 2026-08-06
- 2026-06-30: Operating Lease, Liability, Current $3.15M.
- 2026-03-31: Operating Lease, Liability, Current $3.61M.
- 2025-12-31: Operating Lease, Liability, Current $3.58M.
- 2025-09-30: Operating Lease, Liability, Current $3.54M.
| Period end | Operating Lease, Liability, Current |
|---|---|
| 2026-06-30 | $3.15M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $3.61M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $3.58M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $3.54M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $3.50M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $3.45M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $3.42M 10-K · filed 2026-03-05 |
| 2024-09-30 | $3.39M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $3.35M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $3.27M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $3.23M 10-K · filed 2025-03-10 |
| 2023-09-30 | $3.20M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $3.17M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $3.04M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $3.04M 10-K · filed 2024-03-12 |
| 2022-09-30 | $3.07M 10-Q · filed 2022-11-02 |
| 2022-06-30 | $2.80M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $3.16M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $2.77M 10-K · filed 2023-03-09 |
| 2021-09-30 | $2.70M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $2.61M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $2.51M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $2.44M 10-K · filed 2022-03-10 |
| 2020-09-30 | $2.44M 10-Q · filed 2020-11-25 |
| 2019-12-31 | $2.38M 10-K · filed 2021-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |